NOT-AR-13-013: Notice of NIAMS' Participation in PAR-13-114 Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)

Notice of NIAMS' Participation in PAR-13-114 "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)"

Notice Number: NOT-AR-13-013

Key Dates

Release Date: February 14, 2013

Related Notices

PAR-13-114

Issued by

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

This Notice is to inform potential applicants that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) will participate in the PAR-13-114 "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)" Funding Opportunity Announcement (FOA).

The following sections of PAR-13-114 have been changed to indicate NIAMS participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of General Medical Sciences (NIGMS)

Catalog of Federal Domestics Assistance (CFDA) Number(s)

93.351, 93.847, 93.837, 93.121, 93.859, 93.846

Part 2. Section I. Funding Opportunity Description

Scope

The NIAMS is interested in applications conducting basic and translational research to facilitate the use of stem cell-based therapies for both rare and common diseases/conditions in the NIAMS mission (arthritis, musculoskeletal and skin diseases). Some diseases/conditions that would be of interest include, but are not restricted to, acute injury and chronic degenerative diseases and conditions affecting the musculoskeletal system and skin, as well as monogenic diseases affecting these systems, such as epidermolysis bullosa, some ichthyoses, Duchenne muscular dystrophy, osteogenesis imperfect, osteopetrosis, and chondrodysplasias. Proposed projects can include the improvement of animal disease models for testing stem cell-based therapeutics for these diseases/conditions. Other research areas covered by this FOA may be of interest to NIAMS, provided that the research focuses on musculoskeletal and skin tissues and diseases within the NIAMS mission.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Carl Baker, M.D., Ph.D.
Division of Skin and Rheumatic Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
One Democracy Plaza
6701 Democracy Blvd, Suite 800
Bethesda, MD 20892-4872
Telephone: (301) 594-5017
Email: [email protected]

Fei Wang, Ph.D.
Division of Musculoskeletal Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
One Democracy Plaza
6701 Democracy Blvd, Suite 800
Bethesda, MD 20892-4872
Telephone: (301) 594-5055
Email: [email protected]

Financial/Grants Management Contact(s)

Andrew Jones
Grants Management Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
One Democracy Plaza
6701 Democracy Blvd, Suite 800
Bethesda, MD 20892-4872
Telephone: (301) 451-0610
Email: [email protected]

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to the appropriate NIAMS contact listed above.